The uAspire study is the sponsor of this study and the UNM Psychedelic Assisted Therapy Research Program is the New Mexico site team.
Researchers at the University of New Mexico will be teaming up with Usona Institute to study the use of psilocybin as a treatment for major depressive disorder. This Phase 3 study is designed to deepen our understanding of psilocybin’s potential effectiveness for major depression treatment, durability, and safety.
Listen here to learn more about the use of psilocybin for treating depression with author Charles L. Raison, from Usona Institute, and Rachel Yehuda, PhD from Mount Sinai School of Medicine. LINK
Click on the poster above to view a brochure for the uASPIRE Study.
This is a randomized, double-blind, and multicenter study. The uAspire trial is designed to evaluate the efficacy and safety of psilocybin 25 mg as a treatment for MDD that is administered, with psychosocial support, to adults when they experience a major depressive episode. Following an initial 6-week randomized, double-blind treatment period, participants will be monitored for one year to characterize the treatment durability and long-term safety of psilocybin treatment. To ensure broad applicability of the study findings Usona is committed to the inclusion of adults from diverse backgrounds and treatment settings, including top academic institutions, clinical research sites, and VA medical centers across the country.
For more information regarding uAspire Trial see this link at clinicaltrials.gov
Potential participants who believe they may meet the study criteria may confidentially send their contact information through this link and will be contacted by a member of the research team.
Dan Williams, PhD- Facilitator
A note of gratitude: The psychedelic assisted therapy approach used by our UNM team has been guided by trainings and mentorship from the California Institute of Integral Studies (CIIS), Psychedelic Research and Training Institute (PRATI), Polaris Insight Center, and the Multidisciplinary Association for Psychedelic Studies (MAPS). We are thankful for their guidance. We extend our homage and gratitude to the indigenous peoples who were the originators and holders of the sacred medicine traditions that inform this work today.